46 Reasons why Cannabis Technologies (CAN) will Succeed
Cannabis Technologies has begun trading as InMed Pharmaceuticals (C.IN) since the writing of this article.
1) Investing in biotech can be extremely challenging. There is always a chance that someone will come out with a better product. Typically, it takes a decade or more to approval, followed by commercialization. It usuallycosts tens of millions, to billions of dollars per drug. This can be highly dilutive to a small startup.
2) What if one company had a proprietary cookie cutter system targeting a dozen diseases quicker, cheaper and more effective? I am not sure what Cannabis Technologies will be called in a year from now. I think it will have a new name… perhaps GW Pharmaceuticals or Eli Lily? Or Novartis?
3) Dr. Hossain was chiefly responsible for a $157 million deal with Novartis a decade ago. There was also a $376 million deal with Teva in 2012 based on one of his discoveries. More on that later.
4) Dr. Tarek Mansour (Pfizer) was responsible for multiple FDA approved drugs, where the market value exceeded $1 billion. (Zeffix, Troxatyl, Bosulif, Neratinib and PFE384)
5) The big question is...how many therapy product launches, and strategic partnerships will it take before Big Pharma catches on?
6) The amplitude of possibilities dictates that Cannabis Technologies will one day be a dominant player in the prescription cannabinoid medicine market.
7) Many people now know there are at least 85 different cannabinoids isolated from cannabis exhibiting various effects that could prove therapeutic.
8) They also know that cannabidiol (CBD) alone has shown therapeutic benefits to at least 16 diseases.
9) CAN will take advantage of Strain differences to develop drugs for specific diseases, including:
Glaucoma, Inflammation/Pain/Arthritis, Huntington’s, Epilepsy, Diabetes, Obesity, Cancer & Angiogenesis
10) CAN’s proprietary Cannabinoid Drug Design Platform (“CDP”) allows computer science, statistics, mathematics and engineering to study biological data and processes from the cannabis plant which can be targeted to develop therapies for specific diseases and conditions.
11) What will CAN’s CDP be worth to a company that wants to compete with GWPH…or a better question..what would it be worth to GWPH?
12) The main active ingredients in this are the cannabinoids THC and CBD, but other pharmacologically active cannabinoids are also present and are being investigated.
13) This Platform Technology, combined with CAN’s world renowned scientific team, will enable the company to discover therapies based on proven genomics and unique chemical fingerprints that specific cellular processes leave behind.
14) They will do this both quickly and effectively, with very little money, by outsourcing patented products that are ready for clinical trials and allow a company like Novartis (for example) to absorb all the costs through to commercialization. CAN will retain a fair and reasonable interest that may generate substantial revenue.
Track Record
Dr. Hossain’s successful financial deals based on his drug discoveries over the last 15 years include:
15) 2004: Xenon, Novartis Enter $157M Deal For Obesity Compounds
16) 2006: Xenon and Takeda Announce $75M Agreement To Develop and Commercialize XEN401 for Pain
17) 2006: Xenon Enters Into Anemia Collaboration With Roche ($7 Million for Equity, and $44 Million From Research Funding)
18) 2012: Teva inks $376M deal on Xenon pain program
19) 2009: YM Biosciences Collaboration with the National Research Council of Canada’s Biotechnology Research Institute (NRC-BRI) yielded novel anticancer antibodies that may be safer than similar drugs sold by Genentech/Roche. (another partnership resulted in the production of new breast cancer drug candidates.)
20) 2009: NRC-BRI granted Alethia Biotherapeutics exclusive, worldwide diagnostic rights to a peptide that specifically binds to tumor-associated clusterin in cancer patients.
Who should CAN target?
21) GW Pharmaceuticals has one the broadest clinical pipelines of any company in the marijuana industry…so will CAN.
22) Even though GW may be suffering the typical challenges that all biopharma companies have to endure, with costs far outstripping revenues, they had no problem raising $169.8 million last month.
23) Over 30 years ago, two young men made their way to Vancouver from Seattle to raise money for their software company, and were unfortunately turned down. Their names were Bill Gates and Paul Allen. Very few understood what they had.
24) I think CAN is in the same position today, however, that is changing with Chris Parry writing one of the first articles. Cancer survivor and canabis acdvocate Cheryl Shuman recently endorsed Cannabis Technologies as well.
25) If the billionaire activists want Marijuana to be legalized they most likely would want to facilitate the fast tracking of several revolutionary therapies that will indeed improve the lives of the millions of sufferers around the world.
26) George Soros has spent at least $80 million on the legalization effort since 1994.
27) The late Peter B. Lewis, channeled more than $40 million to influence local debates.
28) The two billionaires’ funding has been unmatched by anyone.
29) Other wealthy activists include: Google billionaire Paul Buchheit, Facebook forefathers Sean Parker and Dustin Moskovitz, and Men’s Wearhouse founder George Zimmer.
30) As of March 31, GWPH had 75 Institutional Holders (sooner or later, they will know about CAN)
31) Analyst Firms Making GWPH Recommendations: Bank of America, Cowen, Piper Jaffray, Leerink Swann, and Morgan Stanley.
Conclusion Check List:
32) World renowned scientific team with multidisciplinary expertise? Check.
33) CSO who has a track record that developed several drugs over 15 years, generating over $500m in revenues? Check
34) Global organizations, governments, and big pharma companies that have previously benefitted from the teams research? Check.
35) Proprietary Cannabinoid Drug Design Platform? Check.
36) Tools to isolate and identify chemical compounds both quickly and effectively? Check.
37) In-house Breeding, Genetics and Cultivation division? Check.
38) Capable of developing compounds for therapies in months rather than years? Check.
39) Target specific diseases and conditions? Check.
40) Outsource early-stage research and trials to conserve capital? Check.
41) Fast Forward through Phase I, Phase II & Phase III quickly and inexpensively compared to traditional Pharma? Check
42) Competitive edge from companies that rely on third-parties to manufacture their treatments? Check
43) Fully-integrated operations to lower costs and increase quality? Check
44) Capable of commercializing therapies in a 1/3 the time of traditional drug development? Check.
45) Anaglous company with a $1.5b market cap? Check
46) Developing medicines for:
– Glaucoma
– Pain and Inflammation
– Orphan Diseases
– Metabolic Disease (Obesity, Diabetes)
– Cancers and Metabolic Diseases? Check.
Dr. Sazzad Hossain, Ph.D., M.Sc.
Chief Scientific Officer
– 20 years of academic and industrial experience in new drug discovery, natural health product development
– Group Leader and Senior Scientist at Biotechnology Research Institute of National Research Council Canada, Government of Canada’s prime biotechnology research organization where he set up pharmacology laboratory to evaluate safety and efficacy of new drugs under development in the areas of cancer, cardiovascular and ocular diseases.
Dr. Tarek S. Mansour, Ph.D., M.Sc.
Scientific Advisor
– Dr. Mansour was responsible for transition of staff and projects to the Pfizer pipeline
-Founder and Chief Executive Officer of Sabila Biosciences LLC, New York
– Under his leadership, several compounds have progressed to various stages of clinical evaluation including FDA approvals and late stage development including:Zeffix, Troxatyl, Bosulif, Neratinib and PFE384.
Dr. Hyder A. Khoja, Ph.D., M.Sc., A.Ag.
Director of Botanical Research and Cultivation
– 17 years of extensive experience in a broad range of life sciences and business services with strong leadership combined with functional expertise and experience in general business management
– Industry experience spans from initiation, operation, and contribution towards developing several research and business proposals in the fields of Agriculture-Food Security, Food Safety & Sovereignty, Alternative energy, Renewable resources, Biofuels, Nutraceutical, Hydroponics, Agriculture & Land use management and Technology transfer
– Presented his work both in at federal government and academic institutions with authorship in over 18 peer-reviewed papers, primarily in genomics, plant physiology, and alternative energy.
–His work was also recognized and appeared in United Nations Food and Agriculture Organization (FAO) Environment and Natural Resources Management as a working paper for Algae-based Biofuels
Craig Schneider
One of Craig’s first companies that he worked for was Ultra Petroleum. The stock dropped from .95 to .45 before blasting through the stratosphere to a stunning pre split price of close to $200. Put another way, the market cap rose from around $3 million to close to $3 Billion!
Loyal investors were rewarded once again in 2006, as he was the cofounder of Magnum Uranium, which was taken over by Energy Fuels in 2009. Shareholders were once again exposed to another potential 1000{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} gain by 2011.
Read more at http://www.stockhouse.com/companies/bullboard/c.can/cannabis-technologies-inc#2FOuXY6qmBPTVqry.99
- Published in Medical Marijuana
HIGHMARK APPOINTS DMYTRO P. YEVTUSHENKO, PHD. AS SCIENTIFIC ADVISOR
Highmark Marketing Inc. has appointed Dr. Dmytro P. Yevtushenko, PhD, as scientific adviser.
Dr. Dmytro P. Yevtushenko is an accomplished scientist in the area of plant biology and biotechnology. He holds a PhD in cell biology from the Institute of Cell Biology & Genetic Engineering, and an MSc in plant physiology and biochemistry (with distinction) from Kiev State University, Ukraine. Dr. Yevtushenko’s research has focused on crop improvement and food safety using modern techniques of molecular biology, genetic engineering and plant tissue culture. In addition, he has a comprehensive knowledge and interest in metabolic bioengineering, secondary metabolite pathways, gene regulation and bioinformatics.
In Dr. Yevtushenko’s past position as director of research and development at Provitro Biosciences LLC, a plant biotechnology company in Mount Vernon, Wash., United States, he worked on the development and implementation of innovative research programs in plant cell and tissue culture. He previously worked as a research associate in the Centre for Forest Biology and senior scientist at SynGene Biotek Inc., department of biochemistry and microbiology at the University of Victoria, B.C., Canada.
Dr. Yevtushenko is the author of over 50 publications, including research articles published in peer-reviewed scientific journals. He has presented major research achievements at numerous scientific conferences, symposia and meetings. He holds two patents, which are on methods to increase plant yield.
As scientific adviser, Dr. Yevtushenko has agreed to provide Highmark with industry intelligence and updates, and to work closely with management to develop business strategies that take advantage of current and future market opportunities.
According to Health Canada, a licensed producer of marijuana must have an employee designated as a quality assurance person who is responsible for assuring the quality of dried marijuana. Highmark is not a licensed producer of marijuana, but it announced in a news release dated June 24, 2014, that it had entered into a binding letter of intent with BCBUD Producers Inc. to acquire 100 per cent of the authorized share capital of BCBUD. BCBUD has an option to lease a 27,000-square-foot building in the township of Langley, B.C. The property is zoned M-2, and when the facility is operational, it could be capable of producing up to two million grams (4,409 pounds) of medical marijuana per year, with the additional possibility of expansion adjacent to the site. BCBUD has prepared an application to become a licensed producer. It is not known if and when BCBUD will obtain the requisite licence. The key milestones to obtaining the licence include filing an application, receiving a ready-to-build notice, completion of the upgrades as per the application, approval to produce upon inspection of the facility and finally approval to distribute the product to patients. If Highmark does become a licensed producer of marijuana, Dr. Yevtushenko will assist Highmark with fulfilling its quality assurance requirements under the Marihuana for Medical Purposes Regulations (MMPR) program.
In addition, and more specifically, the scientific adviser has agreed to make his knowledge and expertise available to advising Highmark regarding research and development on marijuana and marijuana strains, as well as advising on research and development methods with the view to improving yield. Any research and development concerning marijuana may be subject to necessary governmental approval.
As consideration for services provided, Highmark will grant Dr. Yevtushenko, in accordance with the company’s stock option plan, an incentive stock option to purchase 50,000 common shares in the capital of Highmark.
Highmark looks forward to working with Dr. Yevtushenko and learning from his expertise to further Highmark’s business in the medical marijuana sector.
July 9, 2014, news release
Highmark would also like to revise the news release dated July 9, 2014, which announced the close of the first tranche of a non-brokered private placement. Finders were inadvertently described as agents. All other content of that news release remains unchanged.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd. All rights reserved.
- Published in Medical Marijuana
Affinor Growers Completes 45-Acre Land and Facilities Acquisition in Quebec to Produce Strawberries
MONTREAL, CANADA — (Marketwired) — 07/21/14 — Affinor Growers (CSE:AFI)(OTCQB:RSSFF)(FRANKFURT:1AF) (“Affinor” or the “Corporation) has purchased 45 Acres of agriculture property in St-Chrysostome, Quebec, for $340,000.
An offer has been accepted on the 45 acres of prime land south of Montreal and Affinor Growers plans to build a state-of-the-art, strawberry-growing facility in St-Chrysostome, Quebec.
Sebastien Plouffe, president and CEO, comments: “This acquisition is strategically perfect for our distribution plans because it’s located about 30 minutes from Montreal and only few kilometers from the New-York State Border. We’re proud to be able to build the facitliy in the Province of Quebec renowned for it’s agriculture experts and know-how. The Quebec provincial government has incentives for investment into agriculture and job creation, and the Affinor Growers team is excited to explore ways to best collaborate and expand into such a unique culture in Canada. We will be very proactive to begin construction of this facility to satisfy our future clients.”
Update on Affinor Growers:
After completion of due diligence, the Affinor Growers board of directors have decided not to proceed with the LOI signed and announced on June 9, 2014. Fab-All will still continue to build parts for the Vertical Design equipment as Fab-All produces excellent, high quality products.
Affinor Growers will also not complete the land acquistion in Saskatchewan and will instead concentrate it’s effort on building a facility in St-Chrysostome, Quebec and to complete the acquisition of the Vancouver rooftop garden.
About Affinor Growers Inc.
Affinor Growers is a diversified publicly traded company on the Canadian Securities Exchange under the symbol (“AFI”). Affinor is focused on growing high quality crops such as romaine lettuce, spinach, strawberries and high quality medical Marijuana. Affinor is committed to becoming a pre-eminent grower, using exclusive vertical farming techniques.
On Behalf of the Board of Directors AFFINOR GROWERS INC. "Sebastien Plouffe" President & CEO
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release
FORWARD LOOKING INFORMATION
This News Release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This News Release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contacts:
Contact Information
Sebastien Plouffe
President & CEO
(514) 947-2272
splouffe@affinorgrowers.com
http://www.affinorgrowers.com/en
Contact Information
Momentum PR Inc
Max Gagne, President
(514) 913-0351
max@momentumpr.com
Contact Information, spokesperson
Vertical Designs Ltd
Nick Brusatore, CEO
(604) 356-0411
nbrusatore@gmail.com
- Published in Medical Marijuana
Active Component Of Marijuana Has Anti-cancer Effects, Study Suggests
Guillermo Velasco and colleagues, at Complutense University, Spain, have provided evidence that suggests that cannabinoids such as the main active component of marijuana (THC) have anticancer effects on human brain cancer cells.
In the study, THC was found to induce the death of various human brain cancer cell lines and primary cultured human brain cancer cells by a process known as autophagy.
Consistent with the in vitro data, administration of THC to mice with human tumors decreased tumor growth and induced the tumor cells to undergo autophagy. As analysis of tumors from two patients with recurrent glioblastoma multiforme (a highly aggressive brain tumor) receiving intracranial THC administration showed signs of autophagy, the authors suggest that cannabinoid administration may provide a new approach to targeting human cancers.
Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells
Story Source:
The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.
- Published in Medical Marijuana
Washington State Garners $148,256 in Taxes in First Three Days of Legal Cannabis Sales
In the first three days of legal recreational cannabis sales Washington State has earned nearly $150,000 in excise taxes, and that’s with just six outlets open on day one, and that number doesn’t include the money made from state and local sales taxes.
In the first day of sales on Tuesday, the state earned $61,604 in excise taxes. The number dropped to $30,924 on Wednesday, before rising to $55,728 on Thursday, bringing the total to $148,256. The figures were released Friday by the state’s Liquor Control Board, the entity tasked with regulating the new industry.
As a result of the huge introductory demand for legal cannabis in Washington State, Cannabis City, Seattle’s only cannabis outlet, has already sold out, and won’t have any more for as long as two weeks.
In total there are 334 recreational cannabis outlets approved for the state, though most won’t be ready to open until the coming weeks and months.
- Published in Medical Marijuana
Chairman Nick Brusatore of Affinor Growers, Inc. to Be Interviewed LIVE on Clear Channel Business Talk Radio – July 15th, 2014
Chairman Nick Brusatore of Affinor Growers, Inc. to Be Interviewed LIVE on Clear Channel Business Talk Radio – July 15th, 2014
- Published in Medical Marijuana
Wonkbook: Washington’s legal marijuana policy experiment
1. Top story: Washington state’s experiment with legal recreational marijuana begins
Sales of recreational marijuana begin in Washington state. “Washington’s experiment with licensed, legal recreational marijuana began tentatively in a handful of places around the state on Tuesday, with limited supplies…but with great enthusiasm and hoopla in the places where the sales occurred.Where the experiment will lead after the novelty wears off remains deeply uncertain….Possessing marijuana in small amounts and consuming it at home has been legal in Washington for almost two years now…and local law enforcement agencies had mostly backed off enforcing marijuana laws before that. It had not, however, been legal to sell it for recreational purposes until Tuesday.” Kirk Johnson in The New York Times.
Explainer: How the recreational marijuana system in Washington state works. Katy Steinmetz in Time Magazine.
Chart: Where you can maybe buy recreational marijuana. German Lopez in Vox.
Slight problem: There’s a shortage of legal pot. “Although some of Denver’s marijuana shops ran out of product when they opened in January, the kind of shortages expected in Washington are above and beyond….The contrast speaks to just how varied different states’ experiences might be as they strive to legalize marijuana for recreational and medical purposes….Strangely enough, the lack of regulations on the medical marijuana system, which isn’t going through a shortage, could be the saving grace for Washington’s pot enthusiasts. Because the system is so unregulated, many of Washington’s marijuana users already have access to the drug through friends and medical dispensaries….The shortage might only affect curious newcomers and tourists.” German Lopez in Vox.
Interview: Why illegal/unlicensed pot dealers are freaking out. Matt Berman in National Journal.
Lessons from Colorado: A pot learning curve. “The two states have been under scrutiny as they embark on test cases in legalization, watched closely by everyone from legalization critics to advocates pushing legal marijuana in other states, including Oregon and Alaska. Observers are keeping tabs both on how smoothly the rollout goes, as well as looking to the differences in the two states’ approaches….The area of legalization under the most scrutiny in Colorado is the sale of ‘edibles.’…In response to Colorado’s experiences, Washington last month issued some new rules governing the packaging, labeling, and sale of edibles, and it has yet to issue a license for a kitchen to produce such products.” Amanda Paulson in The Christian Science Monitor.
Explainer: 7 differences between Colorado and Washington state’s recreational-marijuana systems. Trevor Hughes in USA Today.
It takes a lot to protect a pot shop. “To protect the people working, the pot and the profits, several layers of security are needed, he said. ‘You can’t cut in from above. You can’t tunnel in from below,’ said Davis, pointing to a maze of circuits on the ceiling. ‘The system will pick you up before you ever manage to get inside.’ Davis also has 14 high-definition, infrared cameras always rolling. Bullet-resistant glass is part of a demolition-resistant wall that customers first see after they walk through the front door. The facility is outfitted with motion sensors, heavy-duty locks and alarms.This, plus panic buttons for the workers, are what’s necessary to deal with cannabis in an all-cash environment, he said.” Natalie Swaby in KING-TV.
What’s the pot-shop experience like? “Seattle’s first pot shop, in an industrial district south of downtown, is no Starbucks. It’s on a busy six-lane road on which trucks frequently rumble by, and it has no off-street parking. The store’s name is in small print above the mailbox. Under state rules, cannabis can’t be displayed in windows and the stores can’t be near schools, playgrounds, libraries, or parks. Inside, glass jewelry cases once used in a Sears (SHLD) department store display pipes and bongs. The bright lights and wood laminate flooring call to mind an optometrist’s shop in a mall, except for the cash machine next to the register. There’s no place to comfortably sit; pot can’t be consumed on the premises.” Peter Robison in Bloomberg Businessweek.
Quotable: “It’s the quality. It’s like a candy store, like chocolates. You can never get enough.” — Deborah Greene, a customer at a new recreational-pot shop in Wash. state. Maria L. La Ganga in Los Angeles Times.
Whose pot is better: Washington’s or Colorado’s? It’s hard to say. “Retailers in Washington braced for long lines and high demand. The same happened when Colorado legalized recreational sales Jan. 1, and tens of thousands of buyers got the chance to pick from a wide variety of strains, from Blue Dream to AK-47 and Facewreck. Those names represent known genetic strains of marijuana plant — think Macintosh and Granny Smith apples — that are cultivated the world over. But even though the genetics are the same, how the plants are grown makes an enormous difference, experts say. That makes it all but impossible to make consistent comparisons.” Trevor Hughes in USA Today.
Explainer: A guide for recreational-marijuana shoppers. Trevor Hughes in USA Today.
Cuomo signs bill legalizing medical pot in N.Y. state. “The measure, which passed both houses of the legislature during the final moments of the legislative session, in June, is significantly more restrictive than other medical-marijuana laws in the nation.” Erica Orden in The Wall Street Journal.
Other legal reads:
Odd couple — Cory Booker, Rand Paul — team up on sentencing reform bill. Ed O’Keefe in The Washington Post.
Mob-busting tool used against online crime. Andrew Grossman in The Wall Street Journal.
Top opinion
PORTER: Blueprints for taming the climate crisis. “It offers a sobering conclusion. We might be able to pull it off. But it will take an overhaul of the way we use energy, and a huge investment in the development and deployment of new energy technologies. Significantly, it calls for an entirely different approach to international diplomacy on the issue of how to combat climate change….But despite these risks, the report offers a promising new path to overcome the decades-old logjam of climate change negotiations. For the first time, when we say we can stop the climate from heating we will more or less know what we are talking about.” Eduardo Porter in The New York Times.
McARDLE: Who’s the real Hobby Lobby bully? “I think…Hobby Lobby and Little Sisters of the Poor are obviously correct — they are being forced by the government to buy something that they don’t want to buy….If it weren’t for state power, the Little Sisters of the Poor would be happily not facilitating the birth-control purchases of its employees; the Barack Obama administration has attempted to force them to do otherwise….All this is old ground. The interesting question is why people on the other side view ceasing the coercion as itself coercive while arguing that the original law did not, in fact, force anyone to violate their religious beliefs.” Megan McArdle in Bloomberg View.
CHAIT: GOP after the apocalypse. “The reformicons’ retreat from Ryan-style apocalypticism is not only a shrewd tonal shift, but also a welcome — albeit unacknowledged — recognition that the party’s doomsaying has not come to pass, and that the American way of life will indeed survive Obama’s reforms. Indeed, the success of Obama’s domestic agenda may create more space for a conservative counteroffensive, in the way that Reaganism opened political room for Bill Clinton. Whether or not the reformicons ever compose a workable domestic agenda, they have come to recognize that they cannot run a presidential campaign promising to rescue America from fire and rubble visible only to themselves.” Jonathan Chait in New York Magazine.
KRUGMAN: Conservative delusions about inflation. “Confronted with a conflict between evidence and what they want to believe for political and/or religious reasons, many people reject the evidence. And knowing more about the issues widens the divide, because the well informed have a clearer view of which evidence they need to reject to sustain their belief system….I found myself thinking about the similar state of affairs when it comes to economics….And if you look at the internal dynamics of the Republican Party, it’s obvious that the currency-debasement, return-to-gold faction has been gaining strength even as its predictions keep failing. Can anything reverse this descent into dogma? A few conservative intellectuals have been trying to persuade their movement to embrace monetary activism, but they’re ever more marginalized.” Paul Krugman in The New York Times.
EDSALL: How much do our genes influence our political beliefs? “It’s been a key question of American politics since at least 1968: Why do so many poor, working-class and lower-middle-class whites — many of them dependent for survival on government programs — vote for Republicans? The debate over the motives of conservative low-income white voters remains unresolved, but two recent research papers suggest that the hurdles facing Democrats in carrying this segment of the electorate may prove difficult to overcome.” Thomas B. Edsall in The New York Times.
WEISER: Sharing the leverage. “In their new book House of Debt, economists Atif Mian and Amir Sufi connect the vast increase in consumer debt with the Great Recession and slow-motion recovery. But rather than sing a requiem for a half-century of proxy Keynesianism…they shout hosannas for even more debt….Complex and opaque debt structures enable politicians and crony capitalists to disguise high leverage while spinning the predictable blowups as black swan events. If a consumer debt hangover is hindering the economy, as Mian and Sufi plausibly argue, then the government should be encouraging writedowns in exchange for the elimination of future guarantees and other hidden debt subsidies. Borrowers and lenders, not taxpayers, should bear the risk.” Jay Weiser in National Review.
Animals interlude: Looks like Grumpy Cat has some company. “Purrmanently sad cat” looks adorably sad all the time.
2. Obama’s requests emergency-funding to deal with the migrant crisis
Obama’s border migrant-crisis funding request faces tough path on Capitol Hill. “Hours after the Obama administration requested $3.7 billion in emergency funding to address the current child immigration crisis at the southern border, few on Capitol Hill were predicting speedy passage — if at all — of legislation to provide Obama with the money he has requested. Instead, the conventional wisdom on the Hill among both Democrats and Republicans is the same as it has been for any number of issues this year — from minimum wage, to unemployment extension, to any number of jobs bills: probably not going to happen.” Wesley Lowery in The Washington Post.
Chart: A breakdown of the White House’s request. The Washington Post.
Border help for HHS, amid a potential new public-health crisis. “Those funds will help HHS provide ‘appropriate care’ for the children, who are mostly coming from El Salvador, Guatemala and Honduras….HHS is one of the agencies responsible for caring for the children, a little-known task that could prove arduous as the number of unaccompanied kids continues to surge. The department’s Unaccompanied Alien Children (UAC) program handled about 6,000 to 8,000 children a year between 2003 and 2011 while they were readied for deportation or took their cases to court. But a new wave of immigrants from Central America means the workload could soar to 90,000 unaccompanied kids this fiscal year and 127,000 in 2015, advocates told The Hill.” Ferdous Al-Faruque in The Hill.
U.N. urges U.S. to treat migrant children as refugees. “People who enter the U.S. and nearby countries illegally from El Salvador, Guatemala and Honduras should not be forced to return home and should be treated as refugees, a U.N. agency says. The U.N. High Commissioner for Refugees says people from those countries are subject to persecution….The call from the U.N. echoes statements made in the spring, when the refugee agency released ‘Children on the Run,’ a report that cited interviews with migrant children who had crossed international borders to flee violence. This week, the U.S. and its neighbors will hold meetings in Nicaragua to discuss ‘updating a 30-year-old declaration regarding the obligations nations have to aid refugees,’ the AP says.” Bill Chappell in NPR.
Obama will visit Perry, but not the border. What will they discuss? “President Barack Obama will meet Texas Governor Rick Perry on Wednesday to discuss a surge of Latin American young people crossing the U.S.-Mexico border that has put the two leaders at odds with each other. Perry’s office welcomed the meeting, to take place in Dallas on the governor’s turf, in a Tuesday statement that said they would discuss the humanitarian and national security crises along the southern border….But the White House said he would not visit the border, a sign that officials do not see a political upside.” Mark Felsenthal and Jon Hershkovitz in Reuters.
Other immigration reads:
Mark Zuckerberg’s immigration push hits brick wall. Jessica Meyers in Politico.
ALDEBOT-GREEN: America’s young refugees. “The president’s solution to change the law governing the processing of unaccompanied youth would be a disaster, particularly for youth who have valid immigration claims. For now, the White House has decided to separate its emergency funding request from these contentious policy changes in order to more carefully consider the competing needs of respecting due process and speeding up removal. This is a good and prudent start to setting better policy in a trying context. No doubt the United States is now facing a refugee crisis within its borders. Yet the administration should not bow to pressure simply to gain political cover. Rather, it should advance policies based on the principle that unaccompanied youth migration is a humanitarian crisis.” Scarlett Aldebot-Green in Foreign Policy.
Wonky caffeine interlude: What does it take to make a decent cup of coffee in space?
3. Improving your experience with your doctor
What are drug companies paying your doctor? You can find out soon. “The financial ties, which naturally raise conflict-of-interest concerns, aren’t always clear, but that’s about to change because of a lesser-known Obamacare provision. Some of the major drugmakers have been reporting some information about financial relationships with care providers — some voluntarily, some as the result of litigation — but a comprehensive nationwide effort is about to launch this summer, and the federal government is now looking to bring even greater transparency. Drug and device companies will now have to report to the government payments to doctors and teaching hospitals of at least $10 (or $100 over the year), and the Medicare agency will soon post the reports in a public database.” Jason Millman in The Washington Post.
Long wait times have become the norm. “One small consolation of our high-priced health care system — our $2.7 trillion collective medical bill — has been the notion that at least we get medical attention quickly. Americans look down on national health systems like Canada’s and Britain’s because of their notorious waiting lists. In recent weeks, the Veterans Affairs hospitals have been pilloried for long patient wait times, with top officials losing their jobs. Yet there is emerging evidence that lengthy waits to get a doctor’s appointment have become the norm in many parts of American medicine, particularly for general doctors but also for specialists. And that includes patients with private insurance as well as those with Medicaid or Medicare.” Elisabeth Rosenthal in The New York Times.
Doctors may soon be paid for not making you wait. “More doctor pay is being tied to patient satisfaction metrics, another sign health care may be coming more consumer-friendly, according to a new national analysis of physician compensation. Already, doctors and hospitals increasingly have more of their pay tied to health outcomes and related clinical measures as medical care moves toward value-based compensation rather than fees for service. But momentum is slowly building for physicians to also be measured on how quickly phone calls are returned to how long a patient sits in a physician office waiting area as part of ‘patient satisfaction metrics’ insurers are working into contracts with medical-care providers.” Bruce Japsen in Forbes.
Preventive services differ between primary care docs and OB/GYNs. “The services women receive during annual preventive care visits may partially depend on what type of doctor they see, suggests a new report. Women who saw primary care doctors for their annual checkup tended to receive a broader range of services, compared to those who saw obstetrician/gynecologists (OB/GYNs), researchers found.” Reuters.
Explainer: 4 medical tests that are awkward, embarrassing, and unnecessary. Sarah Kliff in Vox.
Other health care reads:
Smallpox vials found in storage room of NIH facility. Lena H. Sun and Brady Dennis in The Washington Post.
Without federal action, states move on long-term care. Michael Ollove in Pew Stateline.
U.S. Democrats aim to turn contraception into campaign drive. David Morgan in Reuters.
Food science interlude: The chemistry of why meat browns on the grill, or not.
4. Signs of promise on highway funding, Ex-Im Bank reauthorization
First, highway stopgap funding. “House Ways and Means Committee Chairman Dave Camp (R-Mich.) on Tuesday proposed a transfer of almost $20 billion from the general tax fund to help sustain transportation funding until next April….Without the transfer, federal officials have warned that money for the nation’s major transportation projects would begin to slow after Aug. 1 as the Highway Trust Fund dwindled. Separately, senators said Tuesday that they are nearing an agreement on a plan to replenish the highway fund. Senate Finance Committee Chairman Ron Wyden (D-Ore.) and Sen. Thomas Carper (D-Del.)…declined to specify the parameters of their emerging plan.” Ed O’Keefe and Ashley Halsey III in The Washington Post.
Primary source:
Need to get up to speed? See our previous coverage of this issue.
There’s one problem, though: Can negotiations get done in time? “The plan by House Ways and Means Committee Chairman Dave Camp, a Michigan Republican, would offset its costs by letting employers delay contributions to their employee pension plans, which raises corporate taxable income in a boon for the U.S. Treasury. It also would boost customs user fees and transfer $1 billion from a federal leaking underground storage trust fund. The proposal diverges from a plan in the Senate, complicating the ability to forestall a slowdown in disbursements from the highway trust to states next month.” Laura Litvan in Bloomberg.
And Ex-Im Bank renewal could be part of government funding bill. “High-level discussions between the two chambers are in their infancy….But there are forces in both chambers pushing to renew the Export-Import Bank and pass an extension of the Highway Trust Fund before the election. The House will go first, and plans to extend the Highway Trust Fund sometime in the next two weeks, keeping the program funded until early 2015, Republican sources said. That would give Congress more time to debate a more permanent solution….Senate Majority Leader Harry Reid (D-Nev.) is considering attaching a short-term reauthorization of the Export-Import Bank to a continuing resolution that would keep the government funded past Sept. 30.” John Bresnahan and Jake Sherman in Politico.
S&P issues warns on potential downgrades if Ex-Im renewal falls short. “Political infighting regarding renewal of the charter of a U.S. agency that provides customers of big American corporations with loans for their wares is beginning to have an effect on investor thinking. Standard & Poor’s Monday cautioned Boeing, the largest beneficiary by far of the Export-Import Bank, could face a weakening long-term credit rating should the bank lose its charter.” Greg Morcroft in International Business Times.
Democrats: The party of big business? Not so fast. “Democrats are seeing a new opportunity to rebuild frayed relations with business groups, whose traditional alliance with the Republican Party has been strained by tea-party opposition to rewriting immigration laws, a renewal of the Export-Import Bank and the pursuit of other business priorities….But Democratic outreach faces a big obstacle: Many business leaders, despite their frustrations with the GOP, have a hard time seeing a home in the Democratic Party, with its history of supporting tax increases and government regulation….Business groups in Washington find themselves in a tricky political situation, with anticorporate sentiment on the rise among elements of both parties.” Janet Hook in The Wall Street Journal.
Dancing interlude: Watch Tom Hanks dance to “This Is How We Do It” by Montell Jordan.
5. The NSA just had another bad day
Long read: Meet the Muslim-American leaders the FBI, NSA have been spying on. “Among the Americans on the list are individuals long accused of terrorist activity, including Anwar al-Awlaki and Samir Khan, who were killed in a 2011 drone strike in Yemen. But a three-month investigation by The Intercept…reveals that in practice, the system for authorizing NSA surveillance affords the government wide latitude in spying on U.S. citizens. The five Americans whose email accounts were monitored by the NSA and FBI have all led highly public, outwardly exemplary lives. All five vehemently deny any involvement in terrorism or espionage, and none advocates violent jihad or is known to have been implicated in any crime.” By Glenn Greenwald and Murtaza Hussain in The Intercept.
The government has asked Verizon for information 190,000 times, and it’s only July. “Verizon’s just published its second-ever transparency report, showing that in the first six months of 2014, the company received nearly 149,000 requests for customer data from the government. That’s fewer than the 160,000 times that federal, state and local law enforcement asked Verizon for information on its customers during a similar period in 2013. For the first time, Verizon’s described (albeit in pretty general terms) the number of Americans affected by each request. Of the more than 72,000 requests that came in the form of a subpoena during the first half of the year, 90 percent targeted three or fewer customers, according to the company.” Brian Fung in The Washington Post.
Senate panel advances cybersecurity information-sharing bill, but privacy advocates fear it would give more power to NSA. “The legislation includes provisions aimed at protecting privacy, such as requiring that companies that share information first strip out personally identifiable data (such as names, addresses, and Social Security numbers) of known Americans. But the privacy groups are still worried that the legislation could encourage a company such as Google to turn over vast batches of emails or other private data to the government. The information would go first to the Homeland Security Department, but could then be shared with the NSA or other intelligence agencies.” Brendan Sasso in National Journal.
Primary source: Financial services industry backs Senate bill.
- Published in Blog
Marijuana Sector Positioned to Move Higher as FDA Reviews Drug’s Status
Jun 30, 2014 (ACCESSWIRE via COMTEX) — WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. MDBX -2.31{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and CannaVEST Corp.’s CANV -16.40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} moves lower offset GW Pharmaceuticals plc’s GWPH -7.95{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} modest gains.
Top gainers included Tauriga Sciences Inc. TAUG -8.18{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} , which jumped more than 60{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} after saying that it remains on track with its Honeywood acquisition to commercial products in the medicinal cannabis sector, and Vape Holdings Inc. VAPE -7.69{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} , which jumped more than 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} after reporting results from the soft launch of its e-commerce website HiveCeramics.com last week. The largest decliners included Easton Pharmaceuticals Inc. EAPH -10.67{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} , which fell nearly 20{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} last week.
Cannabis regulatory initiatives and news were mixed last week. While the United Nations warned about a rise in cannabis-related medical cases following legalization efforts, the U.S. FDA indicated that it would reconsider marijuana’s status as a Schedule I Controlled Substance. Legalization efforts have also gained ground in many U.S. states, with Oregon and Alaska becoming two battlegrounds for recreational legalization efforts over the coming year.
What’s New?
– Cannabis Therapy Hemp Farm Measures Up – Cannabis Therapy Corp.’s CTCO -1.00{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} initial hemp cultivars are already well underway measuring in at 16 inches high with normal healthy growth characteristics.
– Cannabis Cultivation Strains Energy Grid – Cannabis cultivation could be putting a strain on the nation’s energy grid, leading some regulators and companies to come up with innovative solutions to the problem.
– A Junior GW Play in the Cannabis Industry – CannabisFN takes a closer look at Cannabis Technologies Inc. CANLF -1.82{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} (cse:CAN), which is being billed by many as a junior GW Pharmaceutials in the making.
– Debunking the Cannabis-Schizophrenia Link – Cannabis critics face a new argument that there may be a reverse association where schizophrenia may cause cannabis use rather than the other way around.
– Cannabis Tech to Begin Phase I Glaucoma Trials – Cannabis Technologies Inc. CANLF -1.82{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} (cse:CAN) announced the start of Phase I clinical trials of its CTI-085 topical cannabinoid therapy for the treatment of glaucoma.
– Abattis Secures Key International Patent – Abattis Bioceuticals Corp. ATTBF -5.21{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} recently secured an International Patent for refining the optimal natural sources of nitric oxide in the human body.
Exclusive Interview Series
In a recent episode of CannabisFN’s Executive Interview Series, Mike Elliott sits down to talk with Cannabis Technologies Inc. CEO Craig Schneider to discuss the company’s Cannabinoid Drug Design Platform and its plans to develop treatments to specific medical conditions utilizing cannabinoids.
Click Here: Watch the Full Interview
What to Watch This Week
The cannabis sector as a whole moved slightly lower last week, but a number of public companies in the space jumped higher. Traders and investors will continue to watch for positive regulatory developments, particularly as the FDA appears ready to review marijuana’s status as a Schedule I Controlled Substance. The removal of that marker could open up the door to new opportunities in the space.
Upcoming Events
– WeedStock Conference – June 29 to July 1, 2014 – The 1st Annual Cannabis Investor Conference in Denver, Colorado will feature networking events, industry speakers, expert panels, and more.
About CannabisFN
CannabisFN.com is a dedicated financial network covering new, emerging and established companies operating in the burgeoning multi-billion dollar medical marijuana (“MMJ”) and cannabis industries. CannabisFN’s coverage is syndicated on the leading industry specific and mainstream financial websites and social media. To learn more and request a media kit, visit http://www.cannabisfn.com/market-defining-companies-program/ .
To subscribe to the CannabisFN newsletter or read additional coverage on cannabis laws and investments, visit http://www.cannabisfn.com .
Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/ .
SOURCE: Emerging Growth LLC
http://www.accesswire.com/img.ashx?id=417375
Copyright 2014 ACCESSWIRE
- Published in Medical Marijuana
Cannabis and Cannabinoids
Cannabinoids are a group of 21-carbon–containing terpenophenolic compounds produced uniquely by Cannabis species (e.g., Cannabis sativa L.) .[1,2] These plant-derived compounds may be referred to as phytocannabinoids. Although delta-9-tetrahydrocannabinol (THC) is the primary psychoactive ingredient, other known compounds with biologic activity are cannabinol, cannabidiol (CBD), cannabichromene, cannabigerol, tetrahydrocannabivarin, and delta-8-THC. CBD, in particular, is thought to have significant analgesic and anti-inflammatory activity without the psychoactive effect (high) of delta-9-THC.
One study in mice and rats suggested that cannabinoids may have a protective effect against the development of certain types of tumors.[3] During this 2-year study, groups of mice and rats were given various doses of THC by gavage. A dose-related decrease in the incidence of hepatic adenoma tumors and hepatocellular carcinoma (HCC) was observed in the mice. Decreased incidences of benign tumors (polyps and adenomas) in other organs (mammary gland, uterus, pituitary, testis, and pancreas) were also noted in the rats. In another study, delta-9-THC, delta-8-THC, and cannabinol were found to inhibit the growth of Lewis lung adenocarcinoma cells in vitro and in vivo .[4] In addition, other tumors have been shown to be sensitive to cannabinoid-induced growth inhibition.[5–8]
Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis invasion and metastasis.[9–12] Two reviews summarize the molecular mechanisms of action of cannabinoids as antitumor agents.[13,14] Cannabinoids appear to kill tumor cells but do not affect their nontransformed counterparts and may even protect them from cell death. These compounds have been shown to induce apoptosis in glioma cells in culture and induce regression of glioma tumors in mice and rats. Cannabinoids protect normal glial cells of astroglial and oligodendroglial lineages from apoptosis mediated by the CB1 receptor.[15]
The effects of delta-9-THC and a synthetic agonist of the CB2 receptor were investigated in HCC.[16] Both agents reduced the viability of HCC cells in vitro and demonstrated antitumor effects in HCC subcutaneous xenografts in nude mice. The investigations documented that the anti-HCC effects are mediated by way of the CB2 receptor. Similar to findings in glioma cells, the cannabinoids were shown to trigger cell death through stimulation of an endoplasmic reticulum stress pathway that activates autophagy and promotes apoptosis. Other investigations have confirmed that CB1 and CB2 receptors may be potential targets in non-small cell lung carcinoma [17] and breast cancer.[18]
An in vitro study of the effect of CBD on programmed cell death in breast cancer cell lines found that CBD induced programmed cell death, independent of the CB1, CB2, or vanilloid receptors. CBD inhibited the survival of both estrogen receptor–positive and estrogen receptor–negative breast cancer cell lines, inducing apoptosis in a concentration-dependent manner while having little effect on nontumorigenic, mammary cells.[19]
CBD has also been demonstrated to exert a chemopreventive effect in a mouse model of colon cancer.[20] In the experimental system, azoxymethane increased premalignant and malignant lesions in the mouse colon. Animals treated with azoxymethane and CBD concurrently were protected from developing premalignant and malignant lesions. In in vitro experiments involving colorectal cancer cell lines, the investigators found that CBD protected DNA from oxidative damage, increased endocannabinoid levels, and reduced cell proliferation. In a subsequent study, the investigators found that the antiproliferative effect of CBD was counteracted by selective CB1 but not CB2 receptor antagonists, suggesting an involvement of CB1 receptors.[21]
Another investigation into the antitumor effects of CBD examined the role of intercellular adhesion molecule-1 (ICAM-1).[12] ICAM-1 expression has been reported to be negatively correlated with cancer metastasis. In lung cancer cell lines, CBD upregulated ICAM-1, leading to decreased cancer cell invasiveness.
In an in vivo model using severe combined immunodeficient mice, subcutaneous tumors were generated by inoculating the animals with cells from human non-small cell lung carcinoma cell lines.[22] Tumor growth was inhibited by 60{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in THC-treated mice compared with vehicle-treated control mice. Tumor specimens revealed that THC had antiangiogenic and antiproliferative effects. However, research with immunocompetent murine tumor models has demonstrated immunosuppression and enhanced tumor growth in mice treated with THC.[23,24]
In addition, both plant-derived and endogenous cannabinoids have been studied for anti-inflammatory effects. A mouse study demonstrated that endogenous cannabinoid system signaling is likely to provide intrinsic protection against colonic inflammation.[25] As a result, a hypothesis that phytocannabinoids and endocannabinoids may be useful in the risk reduction and treatment of colorectal cancer has been developed.[26–29]
CBD may also enhance uptake of cytotoxic drugs into malignant cells. Activation of the transient receptor potential vanilloid type 2 (TRPV2) has been shown to inhibit proliferation of human glioblastoma multiforme cells and overcome resistance to the chemotherapy agent carmustine.[30] In an in vitro model, CBD increased TRPV2 activation and increased uptake of cytotoxic drugs, leading to apoptosis of glioma cells without affecting normal human astrocytes. This suggests that coadministration of CBD with cytotoxic agents may increase drug uptake and potentiate cell death in human glioma cells.
Many animal studies have previously demonstrated that delta-9-THC and other cannabinoids have a stimulatory effect on appetite and increase food intake. It is believed that the endogenous cannabinoid system may serve as a regulator of feeding behavior. The endogenous cannabinoid anandamide potently enhances appetite in mice.[31] Moreover, CB1 receptors in the hypothalamus may be involved in the motivational or reward aspects of eating.[32]
Understanding the mechanism of cannabinoid-induced analgesia has been increased through the study of cannabinoid receptors, endocannabinoids, and synthetic agonists and antagonists. The CB1 receptor is found in both the central nervous system (CNS) and in peripheral nerve terminals. Similar to opioid receptors, increased levels of the CB1 receptor are found in regions of the brain that regulate nociceptive processing.[33] CB2 receptors, located predominantly in peripheral tissue, exist at very low levels in the CNS. With the development of receptor-specific antagonists, additional information about the roles of the receptors and endogenous cannabinoids in the modulation of pain has been obtained.[34,35]
Cannabinoids may also contribute to pain modulation through an anti-inflammatory mechanism; a CB2 effect with cannabinoids acting on mast cell receptors to attenuate the release of inflammatory agents, such as histamine and serotonin, and on keratinocytes to enhance the release of analgesic opioids has been described.[36–38] One study reported that the efficacy of synthetic CB1- and CB2-receptor agonists were comparable with the efficacy of morphine in a murine model of tumor pain.[39]
- Adams IB, Martin BR: Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (11): 1585-614, 1996. [PUBMED Abstract]
- Grotenhermen F, Russo E, eds.: Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential. Binghamton, NY: The Haworth Press, 2002.
- National Toxicology Program: NTP toxicology and carcinogenesis studies of 1-trans-delta(9)-tetrahydrocannabinol (CAS No. 1972-08-3) in F344 rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser 446 (): 1-317, 1996. [PUBMED Abstract]
- Bifulco M, Laezza C, Pisanti S, et al.: Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 148 (2): 123-35, 2006. [PUBMED Abstract]
- Sánchez C, de Ceballos ML, Gomez del Pulgar T, et al.: Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61 (15): 5784-9, 2001. [PUBMED Abstract]
- McKallip RJ, Lombard C, Fisher M, et al.: Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood 100 (2): 627-34, 2002. [PUBMED Abstract]
- Casanova ML, Blázquez C, Martínez-Palacio J, et al.: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 111 (1): 43-50, 2003. [PUBMED Abstract]
- Blázquez C, González-Feria L, Alvarez L, et al.: Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Res 64 (16): 5617-23, 2004. [PUBMED Abstract]
- Guzmán M: Cannabinoids: potential anticancer agents. Nat Rev Cancer 3 (10): 745-55, 2003. [PUBMED Abstract]
- Blázquez C, Casanova ML, Planas A, et al.: Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17 (3): 529-31, 2003. [PUBMED Abstract]
- Vaccani A, Massi P, Colombo A, et al.: Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. Br J Pharmacol 144 (8): 1032-6, 2005. [PUBMED Abstract]
- Ramer R, Bublitz K, Freimuth N, et al.: Cannabidiol inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1. FASEB J 26 (4): 1535-48, 2012. [PUBMED Abstract]
- Velasco G, Sánchez C, Guzmán M: Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12 (6): 436-44, 2012. [PUBMED Abstract]
- Cridge BJ, Rosengren RJ: Critical appraisal of the potential use of cannabinoids in cancer management. Cancer Manag Res 5: 301-13, 2013. [PUBMED Abstract]
- Torres S, Lorente M, Rodríguez-Fornés F, et al.: A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 10 (1): 90-103, 2011. [PUBMED Abstract]
- Vara D, Salazar M, Olea-Herrero N, et al.: Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 18 (7): 1099-111, 2011. [PUBMED Abstract]
- Preet A, Qamri Z, Nasser MW, et al.: Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila) 4 (1): 65-75, 2011. [PUBMED Abstract]
- Nasser MW, Qamri Z, Deol YS, et al.: Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 6 (9): e23901, 2011. [PUBMED Abstract]
- Shrivastava A, Kuzontkoski PM, Groopman JE, et al.: Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 10 (7): 1161-72, 2011. [PUBMED Abstract]
- Aviello G, Romano B, Borrelli F, et al.: Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. J Mol Med (Berl) 90 (8): 925-34, 2012. [PUBMED Abstract]
- Romano B, Borrelli F, Pagano E, et al.: Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol. Phytomedicine 21 (5): 631-9, 2014. [PUBMED Abstract]
- Preet A, Ganju RK, Groopman JE: Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27 (3): 339-46, 2008. [PUBMED Abstract]
- Zhu LX, Sharma S, Stolina M, et al.: Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165 (1): 373-80, 2000. [PUBMED Abstract]
- McKallip RJ, Nagarkatti M, Nagarkatti PS: Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 174 (6): 3281-9, 2005. [PUBMED Abstract]
- Massa F, Marsicano G, Hermann H, et al.: The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 (8): 1202-9, 2004. [PUBMED Abstract]
- Patsos HA, Hicks DJ, Greenhough A, et al.: Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 33 (Pt 4): 712-4, 2005. [PUBMED Abstract]
- Liu WM, Fowler DW, Dalgleish AG: Cannabis-derived substances in cancer therapy–an emerging anti-inflammatory role for the cannabinoids. Curr Clin Pharmacol 5 (4): 281-7, 2010. [PUBMED Abstract]
- Malfitano AM, Ciaglia E, Gangemi G, et al.: Update on the endocannabinoid system as an anticancer target. Expert Opin Ther Targets 15 (3): 297-308, 2011. [PUBMED Abstract]
- Sarfaraz S, Adhami VM, Syed DN, et al.: Cannabinoids for cancer treatment: progress and promise. Cancer Res 68 (2): 339-42, 2008. [PUBMED Abstract]
- Nabissi M, Morelli MB, Santoni M, et al.: Triggering of the TRPV2 channel by cannabidiol sensitizes glioblastoma cells to cytotoxic chemotherapeutic agents. Carcinogenesis 34 (1): 48-57, 2013. [PUBMED Abstract]
- Mechoulam R, Berry EM, Avraham Y, et al.: Endocannabinoids, feeding and suckling–from our perspective. Int J Obes (Lond) 30 (Suppl 1): S24-8, 2006. [PUBMED Abstract]
- Fride E, Bregman T, Kirkham TC: Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood) 230 (4): 225-34, 2005. [PUBMED Abstract]
- Walker JM, Hohmann AG, Martin WJ, et al.: The neurobiology of cannabinoid analgesia. Life Sci 65 (6-7): 665-73, 1999. [PUBMED Abstract]
- Meng ID, Manning BH, Martin WJ, et al.: An analgesia circuit activated by cannabinoids. Nature 395 (6700): 381-3, 1998. [PUBMED Abstract]
- Walker JM, Huang SM, Strangman NM, et al.: Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A 96 (21): 12198-203, 1999. [PUBMED Abstract]
- Facci L, Dal Toso R, Romanello S, et al.: Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 92 (8): 3376-80, 1995. [PUBMED Abstract]
- Ibrahim MM, Porreca F, Lai J, et al.: CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 102 (8): 3093-8, 2005. [PUBMED Abstract]
- Richardson JD, Kilo S, Hargreaves KM: Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75 (1): 111-9, 1998. [PUBMED Abstract]
- Khasabova IA, Gielissen J, Chandiramani A, et al.: CB1 and CB2 receptor agonists promote analgesia through synergy in a murine model of tumor pain. Behav Pharmacol 22 (5-6): 607-16, 2011. [PUBMED Abstract]
- Published in Blog